Literature DB >> 21207060

Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center.

Ashwani K Singal1, Jean-Nicolas Vauthey, James J Grady, John R Stroehlein.   

Abstract

PURPOSE: Recent reports have shown an increase in frequency of intra-hepatic cholangiocarcinoma (IHC) with a stable or decreased frequency of extra-hepatic cholangiocarcinoma (EHC). However, data on the demographic patterns associated with this change are limited. We analyzed cases of cholangiocarcinoma (CC) with aim to study frequency and demographic patterns over time of IHC and EHC.
METHODS: Data were collected from MD Anderson Cancer Center Tumor Registry on CC (1978-2007) and stratified on age (<50, 50-59, 60-69, and ≥70 years), gender, ethnicity (Caucasian, African-American, Hispanic, and Other), time (1978-1987, 1988-1997, 1998-2007), and diagnosis (IHC and EHC). Chi-square tests and logistic regression were used for statistics.
RESULTS: Of 1,061 CC (445 IHC), proportion of IHC increased from 30% in 1978-1998 to 48% during 1998-2007 (P < 0.0001). Compared to EHC, IHC occurred more frequently in relatively young (age < 60 years) (21 and 27% vs. 15 and 23% in 0-49 years and 50-59 years, respectively; P = 0.003) and females (48 vs. 42%, P = 0.03). Ethnic distribution was similar. There was significant (P = 0.019) interaction between age and gender using logistic regression analysis.
CONCLUSIONS: Increase in frequency of IHC occurred over time and is more frequently observed among females <60 years. These data may have implications in understanding pathogenesis of IHC.

Entities:  

Mesh:

Year:  2011        PMID: 21207060     DOI: 10.1007/s00432-010-0971-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States.

Authors:  Katherine A McGlynn; Robert E Tarone; Hashem B El-Serag
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

2.  Descriptive epidemiology of cholangiocarcinoma in Italy.

Authors:  Domenico Alvaro; Emanuele Crocetti; Stefano Ferretti; Maria Consiglia Bragazzi; Riccardo Capocaccia
Journal:  Dig Liver Dis       Date:  2009-12-22       Impact factor: 4.088

3.  Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis.

Authors:  M Kobayashi; K Ikeda; S Saitoh; F Suzuki; A Tsubota; Y Suzuki; Y Arase; N Murashima; K Chayama; H Kumada
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

4.  Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study.

Authors:  Sang Woo Oh; Yeong Sook Yoon; Soon-Ae Shin
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

5.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.

Authors:  Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

6.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

7.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

8.  Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma.

Authors:  S A Khan; M B Toledano; S D Taylor-Robinson
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

9.  Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk? Insights from cancer registry data in Scotland.

Authors:  R Wood; D H Brewster; L A Fraser; H Brown; P C Hayes; O J Garden
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001.

Authors:  J West; H Wood; R F A Logan; M Quinn; G P Aithal
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

View more
  16 in total

1.  Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.

Authors:  Suguru Yamashita; Eugene Jon Koay; Guillaume Passot; Rachna Shroff; Kanwal P Raghav; Claudius Conrad; Yun Shin Chun; Thomas A Aloia; Randa Tao; Ahmed Kaseb; Milind Javle; Christopher H Crane; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2016-12-16       Impact factor: 6.860

2.  Prognostic significance of tumor doubling time in mass-forming type cholangiocarcinoma.

Authors:  Agostino Maria De Rose; Alessandro Cucchetti; Gennaro Clemente; Francesco Ardito; Ivo Giovannini; Giorgio Ercolani; Felice Giuliante; Antonio Daniele Pinna; Gennaro Nuzzo
Journal:  J Gastrointest Surg       Date:  2013-01-05       Impact factor: 3.452

3.  Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.

Authors:  Kulthida Vaeteewoottacharn; Ryusho Kariya; Kouki Matsuda; Manabu Taura; Chaisiri Wongkham; Sopit Wongkham; Seiji Okada
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-23       Impact factor: 4.553

4.  Digital lesion leading to diagnosis of cholangiocarcinoma.

Authors:  Dhauna Karam; Bharat Agrawal; Chandra Mouli
Journal:  BMJ Case Rep       Date:  2017-10-04

5.  Reappraisal of the T Category for Solitary Intrahepatic Cholangiocarcinoma by Tumor Size in 611 Early-Stage (T1-2N0M0) Patients After Hepatectomy: a Surveillance, Epidemiology, and End Results (SEER) Analysis.

Authors:  YiPing Chen; ShanGeng Weng
Journal:  J Gastrointest Surg       Date:  2020-11-02       Impact factor: 3.452

6.  PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.

Authors:  Jurairat Jongthawin; Porncheera Chusorn; Anchalee Techasen; Watcharin Loilome; Thidarut Boonmars; Raynoo Thanan; Anucha Puapairoj; Narong Khuntikeo; Wichittra Tassaneeyakul; Puangrat Yongvanit; Nisana Namwat
Journal:  Tumour Biol       Date:  2014-05-18

7.  TGF-β signaling alters the pattern of liver tumorigenesis induced by Pten inactivation.

Authors:  S M Morris; K T Carter; J Y Baek; A Koszarek; M M Yeh; S E Knoblaugh; W M Grady
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

8.  Atypical presentation of an advanced obstructive biliary cancer without jaundice.

Authors:  Vincent Bryan Salvador; Pushkinder Samrao; Anatoly Leytin; Mohammed Basith
Journal:  Am J Case Rep       Date:  2013-11-06

9.  Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.

Authors:  Yue Gu; Linfeng Xiao; Yanlin Ming; Zhizhong Zheng; Wengang Li
Journal:  Int J Oncol       Date:  2016-03-02       Impact factor: 5.650

10.  Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area.

Authors:  Prakongboon Sungkasubun; Surachate Siripongsakun; Kunlayanee Akkarachinorate; Sirachat Vidhyarkorn; Akeanong Worakitsitisatorn; Thaniya Sricharunrat; Sutida Singharuksa; Rawisak Chanwat; Chairat Bunchaliew; Sirima Charoenphattharaphesat; Ruechuta Molek; Maneenop Yimyaem; Gaidganok Sornsamdang; Kamonwan Soonklang; Kasiruck Wittayasak; Chirayu U Auewarakul; Chulabhorn Mahidol
Journal:  BMC Cancer       Date:  2016-06-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.